CH Biotech R&D Co (TPE:6534) Ending Cash Position: NT$641 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6534 CH Biotech R&D Co Ltd TPE:6534
86 GF Score
Price NT$92.30
GF Value NT$99.22
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is CH Biotech R&D Co Ending Cash Position?

CH Biotech R&D Co TPE:6534 -0.11% 86 Ending Cash Position is NT$641 Mil as of Jun. 2026. GuruFocus rates TPE:6534 with a GF Score™ of 86/100 and a GF Value™ of NT$99.22 (Fairly Valued). The stock has 3 warning signs investors should review.

CH Biotech R&D Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$641 Mil.

CH Biotech R&D Co's quarterly Ending Cash Position increased from Dec. 2025 (NT$394 Mil) to Mar. 2026 (NT$632 Mil) and increased from Mar. 2026 (NT$632 Mil) to Jun. 2026 (NT$641 Mil).

CH Biotech R&D Co's annual Ending Cash Position declined from Dec. 2023 (NT$940 Mil) to Dec. 2024 (NT$479 Mil) and declined from Dec. 2024 (NT$479 Mil) to Dec. 2025 (NT$394 Mil).

CH Biotech R&D Co Ending Cash Position Related Terms

CH Biotech R&D Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for CH Biotech R&D Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CH Biotech R&D Co Ending Cash Position Chart

CH Biotech R&D Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 321.01 530.02 939.93 478.86 394.13

CH Biotech R&D Co Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 626.66 405.29 394.13 631.83 640.73
TPE:6534
86GF Score
CH Biotech R&D Co Ltd TPE:6534
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CH Biotech R&D Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

CH Biotech R&D Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=478.855+-84.727
=394

CH Biotech R&D Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=631.834+8.898
=641

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$641 Mil mean?
CH Biotech R&D Co (TPE:6534) has a Ending Cash Position of NT$641 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CH Biotech R&D Co and its competitors.
Is CH Biotech R&D Co's Ending Cash Position too high?
CH Biotech R&D Co's current Ending Cash Position is NT$641 Mil. Overall, CH Biotech R&D Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's Ending Cash Position compare to CTVA and CF?
CH Biotech R&D Co's Ending Cash Position of NT$641 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for an Agriculture company?
A good Ending Cash Position depends on the Agriculture industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CH Biotech R&D Co and its competitors. CH Biotech R&D Co's current Ending Cash Position is NT$641 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Fairly Valued. The stock's GF Value™ is NT$99.22, compared to a current price of NT$92.30 — trading 7% below its estimated fair value. The current Ending Cash Position is NT$641 Mil. CH Biotech R&D Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current Ending Cash Position is NT$641 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?

Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued. The current stock price of NT$92.30 is trading 7% below its estimated GF Value™ of NT$99.22. GuruFocus considers CH Biotech R&D Co to be Fairly Valued.

Key valuation signals for TPE:6534:

  • Ending Cash Position: NT$641 Mil
  • GF Value™: NT$99.22 vs. price of NT$92.30 (7% below fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CH Biotech R&D Co Business Description

Address No. 89, Wenxian Road, Nantou County, Nantou City, TWN, 540001
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
86GF Score

Get the complete analysis for TPE:6534

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$92.30
Price
NT$99.22
GF Value